Investments in biotechnology are most impactful when made by those with deep pockets. The aim of the game is to make a return on investment, which can only occur when biotech companies can create a profitable product. Without funding from angel investors/venture capitalists, many biotech companies cannot continue to meaningfully function. Analysis of the recent …
Who are FightMND? FightMND are a charity co-founded by Neale Daniher, Pat Cunningham and Dr Ian Davis. The charity aims to raise money to fund important clinical research so that treatments or a cure for MND may be discovered. Since 2014, more than $80 million dollars have been raised by the charity. Much of this …
Read more “FightMND’s Beanie to Cure Pipeline: Where does the money go?”
CRISPR is the future of gene editing in both medicine and agriculture. This article outlines everything you need to know about it!
Read this article to discover more about the newest addition to Melbourne’s biotech hub, Jumar Bioincubator! We discuss who the major players and winners are in the development of Jumar.
Cultivated meat, grown from animal cells in controlled spaces, faces mixed public reception and media scrutiny, crucial for mainstream acceptance and success.
Two Australian stock exchange listed biotech companies, Neuroscientific Biopharmaceuticals LTD and Mesoblast LTD, have experienced upward spikes in share price as a result of positive news released over the Easter holiday.
In a move known as a reverse merger, Exopharm Ltd have acquired Canadian biotech company Tryp Therapeutics, who will occupy Exopharm’s place on the ASX.
In this article: Introduction The drug development pipeline (DDP) is, at its core, the fundamental process that biopharma companies undergo in the quest to bring their therapeutic to market. It is composed of multiple stages that can be lumped into two groups: research and development. The research stages include everything from discovery of a potential …